Hormonal
Women with diabetes have a 30% greater excess risk of cardiovascular disease (CVD) mortality compared to men with diabetes, driven largely by a higher risk of coronary heart disease (CHD) mortality.
Women with diabetes face a 30% higher relative risk of dying from heart disease than men with diabetes. This underscores the importance of rigorous cardiovascular monitoring and prevention for women, potentially requiring more aggressive management than standard protocols might imply.
The pooled multiple-adjusted RRR indicated a 30% significantly greater excess risk of CVD mortality in women with diabetes compared with men (RRR 1.30, 95% CI 1.13 to 1.49; P < 0.001).
Why this rating
Meta-analysis of 23 studies with over 2 million participants.
Source
Sex differences in the association between diabetes and risk of cardiovascular disease, cancer, and all-cause and cause-specific mortality: a systematic review and meta-analysis of 5,162,654 participants
Yafeng Wang et al. · BMC Medicine · 2019
DOI 10.1186/s12916-019-1355-0
More from this paper
- Women with diabetes face a 58% greater risk of coronary heart disease (CHD) mortality and a 13% greater risk of all-cause mortality compared to men with diabetes, indicating a significant sex-specific disparity in cardiovascular outcomes.Strong
- There is no significant sex difference in the relative risk of cancer mortality associated with diabetes; the risk increase is comparable for both men and women.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →